Beware copycat probes after Sanofi generics case
This article was originally published in Scrip
Executive Summary
This week's €40.6 million fine against Sanofi could presage further investigations into the legality of techniques used by pharmaceutical companies to protect their franchises from generic competition. However, with the lack of previous cases addressing the specific abuses brought to light in the Sanofi case, the limits of acceptable practice may be hard to define, and the need for companies to tread carefully is complicated by the difficulty in pinning down future interpretations of legality.